Here's Why Incyte (INCY) is a Strong Value Stock

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks based on valuation ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow, appealing to value investors [3] Growth Score - The Growth Style Score focuses on a company's future prospects and financial health, analyzing projected and historical earnings, sales, and cash flow to find sustainable growth stocks [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like one-week price changes and monthly earnings estimate changes to identify optimal entry points [5] VGM Score - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with strong value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.83% since 1988, outperforming the S&P 500 [7][8] - There are typically over 800 top-rated stocks available, making it essential for investors to utilize Style Scores for better selection [9] Stock to Watch: Incyte Corporation - Incyte Corporation, a biopharmaceutical company, is currently rated 3 (Hold) on the Zacks Rank and has a VGM Score of A, indicating solid potential [12] - The company has a Value Style Score of B, supported by a forward P/E ratio of 14, making it attractive to value investors [13] - Recent analyst revisions have increased earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising to $6.87 per share and an average earnings surprise of +14.4%, positioning Incyte as a noteworthy investment opportunity [13]